Women's Dermatologic Society

  Advances in Dermatology: 2024 in Review  By Cather McKay, MD The past year has been another exciting one in the field of dermatology! New medications and expanded indications give us more options than ever to care for our patients.   Atopic dermatitis and prurigo nodularis More topical options for atopic dermatitis (AD) became available this year with the approval of roflumilast 0.15% cream (Zoryve) in patients aged 6 years and up and tapinarof 1% cream (Vtama) in patients aged 2 years and up. 1,2 Approval of the pan-JAK inhibitor delgocitinib cream for adults with chronic hand eczema is expected based on phase 3 trials. 3 Ruxolitinib cream (Opzelura) is currently approved for ages 12 and up, but has shown safety and efficacy in patients as young as 2 years. 4 IL-13 inhibitor lebrikizumab (Ebglyss) was approved in September for moderate to severe AD in patients 12 years and up who weigh at least 40 kg. 5 Another IL-13 inhibitor, cendakimab, is in develo...

  Advances in Dermatology: 2023 in Review Cather McKay MD, FAAD This year has been yet another exciting year in the field of dermatology with some of the highlights detailed below. Atopic dermatitis, prurigo nodularis, and urticaria The American Academy of Dermatology published guidelines for the management of atopic dermatitis (AD) in adults with topical, light, and systemic therapies this year. 1,2 Topical therapies first used in psoriasis are showing promise in AD. Phosphodiesterase-4 (PDE4) inhibitor roflumilast cream 0.15% (Zoryve) has data available for ages 6 years and up, 3 and a 0.05% cream is proving safe and effective in phase 3 trials for ages 2-5 years. 4 Tapinarof 1% cream (Vtama) is being studied for patients down to the age of 2 years. 5 The indication for oral abrocitinib (Cibinqo) was lowered to the age of 12 this year. Oral baricitinib (Olumiant) is currently approved for alopecia areata in the US but may gain an indication for AD in the...